Headlines
Sputnik developer becomes head of Russia's top vaccine centre
Published by Global Banking & Finance Review®
Posted on December 22, 2025
1 min readLast updated: January 20, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on December 22, 2025
1 min readLast updated: January 20, 2026
Denis Logunov, who developed the Sputnik vaccine, is now head of Moscow's Gamaleya centre, succeeding Alexander Gintsburg.
MOSCOW, Dec 22 (Reuters) - A scientist who developed Russia's Sputnik coronavirus vaccine during the COVID-19 pandemic has been appointed head of Moscow's Gamaleya research centre, the centre said in a statement on Monday.
The statement said that Denis Logunov, 47, will replace Alexander Gintsburg as director of the centre, Russia's leading institution for vaccine research, named after Russian-Soviet scientist Nikolai Gamaleya.
Logunov led the group of scientists who created and tested Sputnik, which was then widely used for COVID-19 vaccination in Russia and other countries, including Argentina, Mexico, Hungary and Serbia.
(Reporting by Gleb Bryanski; Editing by Alexandra Hudson)
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles a disease-causing microorganism.
The Sputnik vaccine is a COVID-19 vaccine developed in Russia, known for its two-dose regimen and was one of the first vaccines approved for emergency use during the pandemic.
A research center is an institution dedicated to conducting research in various fields, often focusing on scientific and technological advancements.
Explore more articles in the Headlines category
